Icosapent ethyl for the treatment of hypertriglyceridemia

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 10, 2013, Pages 1409-1416

  Ballantyne, Christie M ^a   Braeckman, Rene A ^b   Soni, Paresh N ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Amarin Pharma Inc   (United States)

Author keywords

Dyslipidemias; Eicosapentaenoic acid; Hypertriglyceridemia; Omega 3 fatty acids; Triglycerides

Indexed keywords

ATORVASTATIN; DRUG METABOLITE; GLUCOSE; HEMOGLOBIN A1C; ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEPRAZOLE; PRESCRIPTION DRUG; ROSIGLITAZONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; WARFARIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STEADY STATE; TRIACYLGLYCEROL BLOOD LEVEL;

DIETARY SUPPLEMENTS; DRUG APPROVAL; EICOSAPENTAENOIC ACID; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84878864477     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.798645     Document Type: Review

References (57)

1. Miller M, Stone NJ, Ballantyne C, Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333
2. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011;13:544-52
3. Cohen JD, Cziraky MJ, Cai Q, 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. Am J Cardiol 2010;106:969-75
4. Ford ES, Li C, Zhao G, Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009;169:572-8
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
6. Grundy SM, Cleeman JI, Merz CN, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
7. Lovaza [package insert]. GlaxoSmithKline; Research Triangle Park, NC: 2012
8. Vascepa [package insert]. Amarin Pharma, Inc; Bedminster, NJ: 2012
9. Fruchart JC, Sacks FM, Hermans MP, The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008;5:319-35
10. Fletcher B, Berra K, Ades P, Managing abnormal blood lipids: a collaborative approach. Circulation 2005;112:3184-209
11. Ono K. Current concept of reverse cholesterol transport and novel strategy for atheroprotection. J Cardiol 2012;60:339-43
12. Niaspan [package insert]. Abbott Laboratories; North Chicago, IL: 2010
13. Kostner K, Gupta S. Niacin: a lipid polypill? Expert Opin Pharmacother 2008;9:2911-20
14. Brooks EL, Kuvin JT, Karas RH. Niacin's role in the statin era. Expert Opin Pharmacother 2010;11:2291-300
15. Schima SM, Maciejewski SR, Hilleman DE, Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. Expert Opin Pharmacother 2010;11:731-8
16. Reyes-Soffer G, Rondon-Clavo C, Ginsberg HN. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opin Pharmacother 2011;12:1429-38
17. Tricor [package insert]. Abbott Laboratories; North Chicago, IL, 2010
18. Juxtapid [package insert]. Aegerion Pharmaceuticals, Inc; Cambridge, MA: 2012
19. Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs 2010;13:103-11
20. Rizzo M, Wierzbicki AS. New lipid modulating drugs: the role of microsomal transport protein inhibitors. Curr Pharm Des 2011;17:943-9
21. Zargar A, Ito MK. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord 2011;9:255-71
22. Collins N, Tighe AP, Brunton SA, Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr 2008;27:659-66
23. Food and Drug Administration. Overview of dietary supplements. Food and Drug Administration. 2009. Available from: http://www.fda. gov/Food/ DietarySupplements/ConsumerInformation/ucm110417.htm? utm-campaign= Google2&utm-source= fdaSearch&utm-medium=website&utm-term=dietary [Last accessed 26 April 2012]
24. Fish oil and omega-3 fatty acid supplements (EPA and DHA from fish, algae, and krill). Consumer Lab. 2012.Available from: https://www. consumerlab.com/reviews/fish-oil-supplements-review/omega3/[Last accessed 4 May 2012]
25. FDA announces qualified health claims for omega-3 fatty acids. Food and Drug Administration. 2009.Available from: http://www.fda.gov/SiteIndex/ ucm108351.htm [Last accessed 12 September 2012]
26. Skulas-Ray AC, West SG, Davidson MH, Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother 2008;9:1237-48
27. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 2011;13:474-83
28. Jacobson TA, Glickstein SB, Rowe JD, Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012;6:5-18
29. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57
30. Tatsuno I, Saito Y, Kudou K, Efficacy and safety of TAK-085 in comparison with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification the Omega-3 fatty acids Randomized Double-blind (ORD) study. J Clin Lipidol 2013;In press
31. Harris WS, Ginsberg HN, Arunakul N, Safety and efficacy of omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-91
32. Pownall HJ, Brauchi D, Kilinc C, Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999;143:285-97
33. Nettleton JA. Omega-3 fatty acids and health. Springer (formerly Chapman & Hall); New York, NY: 1995
34. Davidson MH, Kling D, Maki KC. Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol 2011;22:437-44
35. Bays HE, Tighe AP, Sadovsky R, Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 2008;6:391-409
36. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006;17:387-93
37. Bays H. Fish oils in the treatment of dyslipidemia and cardiovascular disease. In: Kwiterovich PO, editor. The Johns Hopkins textbook of dyslipidemia. Lippincott Williams & Wolters Kluwer; Philadelphia, PA; 2010. p. 245-57
38. Braeckman RA, Manku MS, Bays HE, Effects of AMR101, a pure EPA omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in patients with very high triglycerides (results from the MARINE trial) [abstract]. Eur Heart J 2011;32(Suppl 1):510-11
39. Bays HE, Ballantyne CM, Kastelein JJ, Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108:682-90 .. MARINE was the pivotal Phase III trial, which led to regulatory approval of icosapent ethyl in patients with very high triglyceride levels
40. Bays HE, Ballantyne CM, Braeckman RA, Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013;13:37-46
41. Bays HE, Braeckman RA, Ballantyne CM, Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol 2012;6:565-72
42. Brunzell JD, Davidson M, Furberg CD, Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-22
43. Ballantyne CM, Bays HE, Kastelein JJ, Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012;110:984-92 .. ANCHOR was the randomized Phase III trial that demonstrated efficacy and safety of icosapent ethyl in statin-treated patients with persistent high triglycerides.
44. Brinton EA, Ballantyne CM, Bays HE, Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract 629-P]. Diabetes 2012;61(Suppl 1):A159-60
45. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007;99:35C-43C
46. Brunton S, Collins N. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids. Curr Med Res Opin 2007;23:1139-45
47. Weitz D, Weintraub H, Fisher E, Fish oil for the treatment of cardiovascular disease. Cardiol Rev 2010;18:258-63
48. Substances affirmed as generally recognized as safe: menhaden oil. Fed Regist 2005;70:14530-2
49. Yokoyama M, Origasa H, Matsuzaki M, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8
50. Epadel [package insert]. Mochida Pharmaceutical Co, Ltd, Tokyo, Japan; 2007
51. Ginsberg HN, Elam MB, Lovato LC, Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
52. Boden WE, Probstfield JL, Anderson T, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
53. Merck announces HPS2-THRIVE study of TREDAPTIVE- (extended-release niacin/laropiprant) did not achieve primary endpoint. Merck & Co., Inc. 2012.Available from: http://www. mercknewsroom.com/press-release/prescription- medicine-news/merckannounces-hps2-thrive-study-tredaptiveextended-relea [Last accessed 6 February 2013]
54. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26
55. Rauch B, Schiele R, Schneider S, OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-9
56. ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18
57. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). 2012.Available from: http://clinicaltrials. gov/show/NCT01492361 [Last accessed 6 February 2013]